Infectious laryngotracheitis (ILT) is a respiratory disease of chicken. Depending on the virus strain mild symptoms as nasal discharge up to lethal forms are observed and can cause massive economical losses. The most efficient way of protection is the immunization with live attenuated vaccines. However, they pose a certain risk of mutating or recombining with field strains, resulting in new pathogenic variants. The need for a safe and efficient vaccine is obvious. We developed a vaccine based on virus-like particles (VLPs) displaying the ILTV glycoproteins gB and gG on their surface. VLPs are neither infectious nor replication competent and offer the opportunity to present antigens in high density. In an in vivo experiment, hatching rate and weight gain revealed no interference with the chicken development. VLP-gG in combination with plasmid encoded chicken interleukin-2 was delivered in ovo, followed by a booster at day 14. This led to the formation of antibodies against gG, which are supposed to prevent the viral immune-evasion mechanisms initiated by gG. In order to elicit cell-mediated immune responses, plasmid encoded interleukin-18 and maleylated VLP-gB were delivered post-hatch which resulted in a shift of the CD4+/CD8+ ratio towards the cytotoxic T-cells. For large scale production, our current aim is to establish a leghorn male hepatoma (LMH) cell line which is able to stably produce VLPs by expressing the coding sequence for the murine leukaemia virus gag. Two different promoters were compared regarding their suitability to drive protein expression: cytomegalovirus (CMV) promoter and chicken beta actin promoter in combination with a CMV early enhancer element and the splice acceptor or the rabbit beta-globin gene. Both plasmids were transfected into LMH-cells by lipofection. Expression of the VLP-forming gag was shown by Western blot analysis. Furthermore, the gag sequence was detected by real time PCR in hygromycin resistant cells.